Amendment: SEC Form SC 13D/A filed by Black Diamond Therapeutics Inc.

Amendment: SEC Form SC 13D/A filed by Black Diamond Therapeutics Inc.

Recent Analyst Ratings for $BDTX

$BDTX Insider Purchases

$BDTX Leadership Updates

$BDTX SEC Filings

$BDTX Large Ownership Changes

$BDTX Analyst Ratings

$BDTX Financials

$BDTX Insider Trading

$BDTX Market Insights

$BDTX Press Releases

Recent Analyst Ratings for
$BDTX

$BDTX
Insider Purchases

$BDTX
Leadership Updates

$BDTX
SEC Filings

$BDTX
Large Ownership Changes

$BDTX
Analyst Ratings

$BDTX
Financials

$BDTX
Insider Trading

$BDTX
Market Insights

$BDTX
Press Releases

Chat with this insight

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Biotech Growth N V bought $934,080 worth of shares (400,000 units at $2.34), increasing direct ownership by 5% to 8,517,839 units (SEC Form 4)

Live Leadership Updates

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

Black Diamond Therapeutics Announces Changes to Board of Directors

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SEC Form 10-Q filed by Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Black Diamond Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Black Diamond Therapeutics Inc.

SEC Form SC 13G filed by Black Diamond Therapeutics Inc.

Amendment: SEC Form SC 13D/A filed by Black Diamond Therapeutics Inc.

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Raymond James initiated coverage on Black Diamond Therapeutics with a new price target

Piper Sandler initiated coverage on Black Diamond Therapeutics

Black Diamond Therapeutics upgraded by Stifel with a new price target

Live finance-specific insights

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Behbahani Ali was granted 3,007 shares, increasing direct ownership by 6% to 57,584 units (SEC Form 4)

Director Campbell Shannon was granted 2,354 shares, increasing direct ownership by 117% to 4,365 units (SEC Form 4)

Director Raman Prakash was granted 2,694 shares, increasing direct ownership by 117% to 4,995 units (SEC Form 4)

Live Market Insights

Piper Sandler Maintains Overweight on Black Diamond Therapeutic, Maintains $12 Price Target

12 Health Care Stocks Moving In Tuesday's Intraday Session

HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target

Fastest customizable press release news feed in the world

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

8/8/24 4:48:56 PM ET

$BDTX

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BDTX alert in real time by email

SC 13D/A 1 d807664dsc13da.htm SC 13D/A SC 13D/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

TO RULE 13d-2(a)

(Amendment No. 6)*

Black Diamond Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

09203E105

(CUSIP Number)

Versant Venture Capital VI, L.P.

Max Eisenberg

One Sansome Street, Suite 1650

San Francisco, CA 94104

415-801-8100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 6, 2024

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.


CUSIP No. 09203E105				13D


1.		Name of Reporting Persons Versant Venture Capital VI, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒(1)
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 3,947,941 shares of common stock (2)
	8.	Shared Voting Power 0
	9.	Sole Dispositive Power 3,947,941 shares of common stock (2)
	10.	Shared Dispositive Power 0

(1)

This Schedule 13D is filed by Versant Venture Capital VI, L.P. (“Versant VI”), Versant Voyageurs I Parallel, L.P. (“Versant I Parallel”), Versant Voyageurs I, L.P. (“Versant Voyageurs I”), Versant Vantage I, L.P. (“Versant Vantage I”), Versant Ventures VI GP, L.P. (“Versant Ventures VI GP”), Versant Ventures VI GP-GP, LLC (“Versant Ventures VI GP-GP”), Versant Voyageurs I GP, L.P. (“Versant Voyageurs I GP LP”), Versant Voyageurs I GP Company (“Versant Voyageurs I GP”), Versant Vantage I GP, L.P. (“Versant Vantage I GP LP”) and Versant Vantage I GP-GP, LLC (“Versant Vantage I GP-GP” and, with Versant VI, Versant I Parallel, Versant Voyageurs I, Versant Vantage I, Versant Ventures VI GP, Versant Ventures VI GP-GP, Versant Voyageurs I GP LP, Versant Voyageurs I GP, and Versant Vantage I GP LP, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)	These shares are held by Versant VI. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP share voting and dispositive power with respect to the shares held by Versant VI.

(3)

The percentages used herein are calculated based upon 56,504,895 shares issued and outstanding as of August 1, 2024 as set forth in the Issuer’s quarterly report on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on August 6, 2024 (the “Form 10-Q”).


CUSIP No. 09203E105				13D


1.		Name of Reporting Persons Versant Ventures VI GP, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒(1)
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 4,328,883 shares of common stock (2)
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 4,328,883 shares of common stock (2)

(1)	This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

Includes (i) 3,947,941 shares held by Versant VI and (ii) 380,942 shares held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP share voting and dispositive power with respect to the shares held by Versant VI and Versant I Parallel.

(3)	The percentages used herein are calculated based upon 56,504,895 shares issued and outstanding as of August 1, 2024 as set forth in the Form 10-Q.


CUSIP No. 09203E105				13D


1.		Name of Reporting Persons Versant Ventures VI GP-GP, LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒(1)
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 4,328,883 shares of common stock (2)
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 4,328,883 shares of common stock (2)

(1)	This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

(3)	The percentages used herein are calculated based upon 56,504,895 shares issued and outstanding as of August 1, 2024 as set forth in the Form 10-Q.


CUSIP No. 09203E105				13D


1.		Name of Reporting Persons Versant Voyageurs I Parallel, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒(1)
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Ontario Canada


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 380,942 shares of common stock (2)
	8.	Shared Voting Power 0
	9.	Sole Dispositive Power 380,942 shares of common stock (2)
	10.	Shared Dispositive Power 0

(1)	This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

These shares are held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Each of Versant Voyageurs I GP LP, Versant Ventures VI GP and Versant Ventures VI GP-GP share voting and dispositive power with respect to the shares held by Versant I Parallel.

(3)	The percentages used herein are calculated based upon 56,504,895 shares issued and outstanding as of August 1, 2024 as set forth in the Form 10-Q.


CUSIP No. 09203E105				13D


1.		Name of Reporting Persons Versant Voyageurs I GP, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒(1)
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 380,942 shares of common stock (2)
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 380,942 shares of common stock (2)

(1)	This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

(3)	The percentages used herein are calculated based upon 56,504,895 shares issued and outstanding as of August 1, 2024 as set forth in the Form 10-Q.


CUSIP No. 09203E105				13D


1.		Name of Reporting Persons Versant Voyageurs I, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒(1)
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Ontario Canada


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 1,277,541 shares of common stock (2)
	8.	Shared Voting Power 0
	9.	Sole Dispositive Power 1,277,541 shares of common stock (2)
	10.	Shared Dispositive Power 0

(1)	This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)	These shares are held by Versant Voyageurs I. Versant Voyageurs I GP is the general partner of Versant Voyageurs I and shares voting and dispositive power with respect to the shares held by Versant Voyageurs I.

(3)	The percentages used herein are calculated based upon 56,504,895 shares issued and outstanding as of August 1, 2024 as set forth in the Form 10-Q.


CUSIP No. 09203E105				13D


1.		Name of Reporting Persons Versant Voyageurs I GP Company
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒(1)
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Nova Scotia, Canada


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 1,277,541 shares of common stock (2)
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 1,277,541 shares of common stock (2)

(1)	This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)	These shares are held by Versant Voyageurs I. Versant Voyageurs I GP is the general partner of Versant Voyageurs I and shares voting and dispositive power with respect to the shares held by Versant Voyageurs I.

(3)	The percentages used herein are calculated based upon 56,504,895 shares issued and outstanding as of August 1, 2024 as set forth in the Form 10-Q.


CUSIP No. 09203E105				13D


1.		Name of Reporting Persons Versant Vantage I, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒(1)
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 822,140 shares of common stock (2)
	8.	Shared Voting Power 0
	9.	Sole Dispositive Power 822,140 shares of common stock (2)
	10.	Shared Dispositive Power 0

(1)	This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

These shares are held by Versant Vantage I. Versant Vantage I GP LP is the general partner of Versant Vantage I and Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Each of Versant Vantage I GP LP and Versant Vantage I GP-GP share voting and dispositive power with respect to the shares held by Versant Vantage I.

(3)	The percentages used herein are calculated based upon 56,504,895 shares issued and outstanding as of August 1, 2024 as set forth in the Form 10-Q.


CUSIP No. 09203E105				13D


1.		Name of Reporting Persons Versant Vantage I GP, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒(1)
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 822,140 shares of common stock (2)
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 822,140 shares of common stock (2)

(1)	This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

These shares are held by Versant Vantage I. Versant Vantage I GP LP is the general partner of Versant Vantage I, and Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Each of Versant Vantage I GP LP and Versant Vantage I GP-GP share voting and dispositive power with respect to the shares held by Versant Vantage I.

(3)	The percentages used herein are calculated based upon 56,504,895 shares issued and outstanding as of August 1, 2024 as set forth in the Form 10-Q.


CUSIP No. 09203E105				13D


1.		Name of Reporting Persons Versant Vantage I GP-GP, LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒(1)
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 822,140 shares of common stock (2)
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 822,140 shares of common stock (2)

(1)	This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

(2)

(3)	The percentages used herein are calculated based upon 56,504,895 shares issued and outstanding as of August 1, 2024 as set forth in the Form 10-Q.


CUSIP No. 09203E105				13D

Explanatory Note:

This Amendment No. 6 (this “Amendment”) amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the “Commission”) on February 13, 2020, as amended by Amendment No. 1 filed with the Commission on August 21, 2020, Amendment No. 2 filed with the Commission on September 25, 2020, Amendment No. 3 filed with the Commission on November 23, 2020, Amendment No. 4 filed with the Commission on December 3, 2020, and Amendment No. 5 filed with the Commission on November 9, 2023 (collectively, the “Original Schedule 13D”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.

Item 5. Interest in Securities of the Issuer

This information reported below is based on a total of 56,504,895 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported on the Issuer’s Form 10-Q filed with the Commission on August 6, 2024. This Amendment is being filed to update the aggregate percentage of the Issuer’s Common Stock owned by the Reporting Persons due to dilution caused by the Issuer’s sales of additional shares of its Common Stock from time to time since the date of the filing of the Original Schedule 13D. Such transactions resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Original Schedule 13D.

(a) and (b) See Items 7-11 of the cover pages of this Amendment and Item 2 above.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


August 8, 2024

Versant Venture Capital VI, L.P.

By:		Versant Ventures VI GP, L.P.
Its:		General Partner
By:		Versant Ventures VI GP-GP, LLC
Its:		General Partner

By:		/s/ Max Eisenberg, Chief Operating Officer

Versant Ventures VI GP, L.P.

By:		Versant Ventures VI GP-GP, LLC
Its:		General Partner

By:		/s/ Max Eisenberg, Chief Operating Officer

Versant Ventures VI GP-GP, LLC

By:		/s/ Max Eisenberg, Chief Operating Officer

Versant Voyageurs I Parallel, L.P.

By:		Versant Voyageurs I GP, L.P.
Its:		General Partner
By:		Versant Ventures VI GP, L.P.
Its:		General Partner
By:		Versant Ventures VI GP-GP, LLC
Its:		General Partner

By:		/s/ Max Eisenberg, Chief Operating Officer

Versant Voyageurs I GP, L.P.

By:		Versant Ventures VI GP, L.P.
Its:		General Partner
By:		Versant Ventures VI GP-GP, LLC
Its:		General Partner

/s/ Max Eisenberg, Chief Operating Officer

Versant Voyageurs I, L.P.

By:		Versant Voyageurs I GP Company
Its:		General Partner

/s/ Max Eisenberg, Chief Operating Officer


Versant Voyageurs I GP Company

/s/ Max Eisenberg, Chief Operating Officer

Versant Vantage I, L.P.

By:		Versant Vantage I GP, L.P.
Its:		General Partner
By:		Versant Vantage I GP-GP, LLC
Its:		General Partner

/s/ Max Eisenberg, Chief Operating Officer

Versant Vantage I GP, L.P.

By:		Versant Vantage I GP-GP, LLC
Its:		General Partner

/s/ Max Eisenberg, Chief Operating Officer

Versant Vantage I GP-GP, LLC

/s/ Max Eisenberg, Chief Operating Officer

Get the next $BDTX alert in real time by email

Date	Price Target	Rating	Analyst
7/31/2024	$20.00	Outperform	Raymond James
7/14/2023		Overweight	Piper Sandler
6/30/2023	$2.00 → $10.00	Hold → Buy	Stifel
6/28/2023	$11.00	Neutral → Buy	H.C. Wainwright
6/27/2023	$10.00	Neutral → Outperform	Wedbush
3/29/2022		Outperform → Neutral	Wedbush
3/22/2022		Buy → Neutral	H.C. Wainwright
9/30/2021	$10.00	Hold	Stifel

Aggregate Amount Beneficially Owned by Each Reporting Person

3,947,941 shares of common stock (2)

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

☐

Percent of Class Represented by Amount in Row 11

7.0% (3)

Type of Reporting Person (See Instructions)

PN